Your browser doesn't support javascript.
loading
Recurrent Clostridium difficile infection: From colonization to cure.
Shields, Kelsey; Araujo-Castillo, Roger V; Theethira, Thimmaiah G; Alonso, Carolyn D; Kelly, Ciaran P.
Afiliación
  • Shields K; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, United States. Electronic address: ksshield@bidmc.harvard.edu.
  • Araujo-Castillo RV; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Lowry Medical Office Building, Suite GB 110 Francis Street, Boston, MA 02215, United States. Electronic address: raraujo@bidmc.harvard.edu.
  • Theethira TG; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, United States. Electronic address: ttheethi@bidmc.harvard.edu.
  • Alonso CD; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Lowry Medical Office Building, Suite GB 110 Francis Street, Boston, MA 02215, United States. Electronic address: calonso@bidmc.harvard.edu.
  • Kelly CP; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, United States. Electronic address: ckelly2@bidmc.harvard.edu.
Anaerobe ; 34: 59-73, 2015 Aug.
Article en En | MEDLINE | ID: mdl-25930686
Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Portador Sano / Clostridioides difficile / Infecciones por Clostridium Tipo de estudio: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Anaerobe Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Portador Sano / Clostridioides difficile / Infecciones por Clostridium Tipo de estudio: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Anaerobe Año: 2015 Tipo del documento: Article